Bruker Corp (BRKRP) — SEC Filings
Bruker Corp (BRKRP) — 45 SEC filings. Latest: 8-K (Dec 9, 2025). Includes 25 8-K, 9 SC 13G/A, 6 10-Q.
Overview
Bruker Corp (BRKRP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Bruker Corporation reported a significant net loss of $59.6 million for the three months ended September 30, 2025, a stark contrast to the net income of $40.9 million in the same period of 2024. This downturn was primarily driven by a goodwill impairment charge of $96.5 million in Q3 2025, where no
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Bruker Corp is neutral.
Filing Type Overview
Bruker Corp (BRKRP) has filed 25 8-K, 6 10-Q, 1 DEFA14A, 2 10-K, 9 SC 13G/A, 1 8-K/A, 1 DEF 14A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of BRKRP's 33 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $860.5M |
| Net Income | -$59.6M |
| EPS | -$0.41 |
| Debt-to-Equity | 0.81 |
| Cash Position | $293.1M |
| Operating Margin | N/A |
| Total Assets | $6,434.9M |
| Total Debt | $1,984.2M |
Key Executives
- Dr. Michael E. DeBakey
- Ms. Susan L. Miller
- Rohan A. Kamath
- Dr. Robert J. Massie
- Ms. Susan L. Spradling
- Mr. Justin L. Smith
- Mr. Michael B. Williamson
- Abigail P. Johnson
Industry Context
Bruker Corporation operates in the scientific instruments and life science tools market, a sector characterized by innovation and demand driven by research and development in areas like healthcare, diagnostics, and materials science. The industry is competitive, with companies focusing on advanced technologies and integrated solutions to capture market share. Trends include increasing demand for high-throughput screening, personalized medicine, and advanced analytical techniques.
Top Tags
material-agreement (6) · amendment (5) · 8-k (5) · 10-Q (4) · financials (4) · financial-obligation (4) · corporate-governance (3) · financial-reporting (3) · financial-results (3) · sec-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $59.6M | Attributable to common shareholders for Q3 2025, a significant swing from $40.9M net income in Q3 2024. |
| Goodwill Impairment Charge | $96.5M | Recorded in Q3 2025, a primary driver of the net loss. |
| Total Revenue | $860.5M | For Q3 2025, a slight decrease from $864.4M in Q3 2024. |
| Nine-Month Net Loss | $34.6M | Attributable to common shareholders for the nine months ended September 30, 2025, compared to $99.4M net income in the prior year period. |
| Cash and Cash Equivalents | $293.1M | As of September 30, 2025, an increase from $183.4M at December 31, 2024. |
| Preferred Stock Proceeds | $669.5M | Net proceeds from the issuance of Series A Mandatory Convertible Preferred Stock in Q3 2025. |
| Long-Term Debt | $1,984.2M | As of September 30, 2025, a decrease from $2,061.8M at December 31, 2024. |
| Total Assets | $6,434.9M | As of September 30, 2025, an increase from $5,806.7M at December 31, 2024. |
| Basic EPS Loss | $0.41 | For Q3 2025, compared to $0.27 basic EPS income in Q3 2024. |
| SEC File Number | 000-30833 | Identifies Bruker Corporation's filing history |
| IRS Employer Identification No. | 04-3110160 | Tax identification for Bruker Corporation |
| Revenue for Q2 2025 | $750.5M | Increased from $680.2 million in Q2 2024, showing strong growth. |
| Net income attributable to Bruker Corp shareholders for Q2 2025 | $105.3M | Increased from $88.7 million in Q2 2024, indicating improved profitability. |
| Research and Development expenses for Q2 2025 | $75.1M | Reflects continued investment in innovation and future product development. |
| Cost of Revenue for Q2 2025 | $340.2M | Increased in line with higher revenue, but gross margin remained healthy. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, passive stake in Bruker Corp. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"Bruker Corp.'s stock price will not be significantly impacted by this passive ownership update.","entity":"BRUKER CORP","targetDate":"2024-03-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bruker Corp (BRKRP)?
Bruker Corp has 45 recent SEC filings from Jan 2024 to Dec 2025, including 25 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BRKRP filings?
Across 45 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 42 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Bruker Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bruker Corp (BRKRP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bruker Corp?
Key financial highlights from Bruker Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BRKRP?
The investment thesis for BRKRP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bruker Corp?
Key executives identified across Bruker Corp's filings include Dr. Michael E. DeBakey, Ms. Susan L. Miller, Rohan A. Kamath, Dr. Robert J. Massie, Ms. Susan L. Spradling and 3 others.
What are the main risk factors for Bruker Corp stock?
Of BRKRP's 33 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 25 low-risk.
What are recent predictions and forward guidance from Bruker Corp?
Recent forward-looking statements from Bruker Corp include guidance on {"claim":"FMR LLC will maintain a significant, passive stake in Bruker Corp. for the foreseeable future.","entity":"FMR and 1 other predictions.